Spectral Flow Cytometry Special Report
- Megan McCausland, Q² Solutions
- Christopher Groves, SCYM(ASCP)CM, Q² Solutions
- Tania Nevers, Ph.D., Bristol Myers Squibb
- Yi-Dong Lin, Ph.D., GlaxoSmithKline
- Vilma Decman, Ph.D., GlaxoSmithKline
The use of spectral Flow Cytometry has the potential to significantly increase the data collected through clinical studies. Recent technology advancements and increased availability of fluorochromes have resulted in a dramatic rise in the complexity and dimensionality of flow cytometry panels. While increasing the panel size enables detection of a broader spectrum of markers and subpopulations, even in small biological samples, it also introduces several obstacles in panel design, optimization, and downstream data processing and interpretation.
In this collaborative special report in Bioanalysis, the authors share their experiences and methodologies for developing high-dimensional panels for the Aurora spectral flow cytometer to facilitate enhanced clinical sample analysis.
Read the report.